Abstract
Type 2 diabetes incidence is rising at an alarming rate across the globe. Previous research has shown increased rates of metabolic syndrome and type 2 diabetes in cancer survivors following treatment with cisplatin, a commonly used chemotherapeutic agent. The goal of our research is to determine if cisplatin treatment puts cancer survivors at greater risk for developing type 2 diabetes, due in part to off-target damage to pancreatic β cells. To study the effects of cisplatin on β cells, we treated immortalized β cells (INS-1) and primary mouse islets with 10 μM cisplatin or vehicle for 48 hours in vitro.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
